Feng joined Acurion with over 20 years of experience in molecular diagnostics.  He was the CTO at Epic Sciences, working on a liquid biopsy test for metastatic breast cancer.  He was also the VP of R&D at Castle Biosciences, a public company with a focus on melanoma and esophagus cancer.  Prior to that, Feng was the COO at AltheaDx, where he led the effort to secure the Medicare coverage of a pharmacogenomics test for depression and anxiety.  Earlier in his career, Feng worked at Hologic and Third Wave Technologies, where he was part of the team that developed and launched the first FDA-cleared companion diagnostics test for a colorectal cancer drug.  Feng has a PhD in Cell Biology from Medical College of Wisconsin and an MS in Computer Science from Marquette University.